Publicación:
Effects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trial

Página de artículo simple
dc.contributor.authorLopez-Jaramillo, Patriciospa
dc.contributor.authorDagenais, Gillesspa
dc.contributor.authorJung, Hyejungspa
dc.contributor.authorLonn, Evaspa
dc.contributor.authorBogaty, Peter M.spa
dc.contributor.authorDehghan, Mahshidspa
dc.contributor.authorHeld, Claesspa
dc.contributor.authorAvezum, Alvarospa
dc.contributor.authorPetr, Janskyspa
dc.contributor.authorKeltai, Matyasspa
dc.contributor.authorLawrence A., Leiterspa
dc.contributor.authorToff, William D.spa
dc.contributor.authorBosch, Jackiespa
dc.contributor.authorYusuf, Salimspa
dc.date.accessioned2019-06-20T13:35:30Zspa
dc.date.available2019-06-20T13:35:30Zspa
dc.date.issued2018spa
dc.description11 p.spa
dc.description.abstractBackground-—It is not clear whether the effects of lipid-lowering or antihypertensive medications are influenced by adherence to healthy lifestyle factors. We assessed the effects of both drug interventions in subgroups by the number of healthy lifestyle factors in participants in the HOPE-3 (Heart Outcomes Prevention Evaluation) trial. Methods and Results-—In this primary prevention trial, 4 healthy lifestyle factors (nonsmoking status, physical activity, optimal body weight, and healthy diet) were recorded in 12 521 participants who were at intermediate risk of cardiovascular disease (CVD) and were randomized to rosuvastatin, candesartan/hydrochlorothiazide, their combination, or matched placebos. Median follow-up was 5.6 years. The outcome was a composite of CVD events. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression models. Participants with ≥2 healthy lifestyle factors had a lower rate of CVD compared with those with fewer factors (HR: 0.85; 95% CI, 0.73–1.00). Rosuvastatin reduced CVD events in participants with ≥2 healthy lifestyle factors (HR: 0.74; 95% CI, 0.62–0.90) and in participants with <2 factors (HR: 0.79; 95% CI, 0.61–1.01). Consistent results were observed with combination therapy (≥2 factors: HR: 0.74; 95% CI, 0.57–0.97; <2 factors: HR: 0.61; 95% CI, 0.43–0.88). Candesartan/hydrochlorothiazide tends to reduce CVD only in participants with <2 healthy lifestyle factors (HR: 0.78; 95% CI, 0.61–1.00). Conclusions-—Healthy lifestyles are associated with lower CVD. Rosuvastatin alone and combined with candesartan/hydrochlorothiazide is beneficial regardless of healthy lifestyle status; however, the benefit of antihypertensive treatment appears to be limited to patients with less healthy lifestyles.eng
dc.format.mimetypeapplication/pdfspa
dc.identifier.doi10.1161/JAHA.118.008918spa
dc.identifier.issn2047-9980spa
dc.identifier.urihttps://repositorio.udes.edu.co/handle/001/3168spa
dc.language.isoengspa
dc.relation.ispartofJournal of the American Heart Associationeng
dc.rightsDerechos Reservados - Universidad de Santander, 2018spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)spa
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/spa
dc.sourcehttps://www.ahajournals.org/doi/pdf/10.1161/JAHA.118.008918eng
dc.subject.proposalAntihypertensive agenteng
dc.subject.proposalStatineng
dc.titleEffects of lipid-lowering and antihypertensive treatments in addition to healthy lifestyles in primary prevention : An analysis of the HOPE-3 trialeng
dc.typeArtículo de revistaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/articlespa
dc.type.redcolhttp://purl.org/redcol/resource_type/ARTspa
dc.type.versioninfo:eu-repo/semantics/publishedVersionspa
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
Archivos
Paquete original
Mostrando 1 - 1 de 1
Imagen en miniatura
Nombre:
Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention An Analysis of the HOPE 3 Trial.pdf
Tamaño:
348.1 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo Principal
Descargar
Paquete de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
59 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
Colecciones
AGBBA. Artículos de Investigación